BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25972063)

  • 1. Long-Term Survival of Patient with Epstein-Barr Virus-Positive Gastric Cancer Treated with Chemotherapy: Case Report.
    Yanai H; Yahara N; Furuya T; Hayashi H; Murakami T; Shimokawa Y; Sugihara S
    J Gastrointest Cancer; 2016 Mar; 47(1):107-10. PubMed ID: 25972063
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
    Bodoky G; Scheulen ME; Rivera F; Jassem J; Carrato A; Moiseyenko V; Vynnychenko I; Prausová J; Van Laethem JL; Cascinu S; Ajani JA
    J Gastrointest Cancer; 2015 Jun; 46(2):109-17. PubMed ID: 25707610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma.
    Min BH; Tae CH; Ahn SM; Kang SY; Woo SY; Kim S; Kim KM
    Gastric Cancer; 2016 Jul; 19(3):852-9. PubMed ID: 26265391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
    Kim SG; Hwang SH
    World J Surg Oncol; 2016 Apr; 14():102. PubMed ID: 27039375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.
    Saito M; Kiyozaki H; Takata O; Suzuki K; Rikiyama T
    World J Surg Oncol; 2014 Dec; 12():406. PubMed ID: 25551581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
    Huang DZ; Xiong JP; Xu N; Yan Z; Zhuang ZX; Yu Z; Wan HP; Zhang Y; Deng T; Zheng RS; Guo ZQ; Hu CH; Wang ML; Yu ZH; Yao Y; Meng JC; Ba Y
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):865-8. PubMed ID: 23291139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response of metastatic gastric cancer to chemoimmunotherapy.
    Ina K; Furuta R
    Indian J Med Res; 2017 Jul; 146(1):141. PubMed ID: 29168471
    [No Abstract]   [Full Text] [Related]  

  • 8. Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
    Kim JY; Do YR; Park KU; Kim JG; Chae YS; Kim MK; Lee KH; Ryoo HM; Bae SH; Baek JH; Song HS
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):527-32. PubMed ID: 20461377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial.
    Yoshikawa T; Tanabe K; Nishikawa K; Ito Y; Matsui T; Kimura Y; Hirabayashi N; Mikata S; Iwahashi M; Fukushima R; Takiguchi N; Miyashiro I; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J
    Ann Surg Oncol; 2014 Jan; 21(1):213-9. PubMed ID: 23838904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
    Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
    Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of gastric cancer in Asia: the missing link.
    Nishida T
    Lancet Oncol; 2009 Nov; 10(11):1027-8. PubMed ID: 19880057
    [No Abstract]   [Full Text] [Related]  

  • 13. Just when you thought the fluorouracil debate was over: S-1 and gastric cancer.
    Ilson D
    J Clin Oncol; 2005 Oct; 23(28):6826-8. PubMed ID: 16145059
    [No Abstract]   [Full Text] [Related]  

  • 14. [Results of chemotherapy using new anti-cancer drugs since S-1 for advanced or recurrent gastric cancer in our institute].
    Sato T; Kikuchi Y; Saito T; Hirano S; Kouzuma T
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1819-25. PubMed ID: 18030016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.
    Li YH; Qiu MZ; Xu JM; Sun GP; Lu HS; Liu YP; Zhong MZ; Zhang HL; Yu SY; Li W; Hu XH; Wang JJ; Cheng Y; Zhou JT; Guo ZQ; Guan ZG; Xu RH
    Oncotarget; 2015 Oct; 6(33):35107-15. PubMed ID: 26439700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
    Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
    Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
    Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy].
    Kita K; Takahashi M; Nakano S; Akabane H; Yanagida N; Shomura H; Hanamoto T; Kuji M; Oikawa F; Miyagi H
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2281-3. PubMed ID: 20037396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.
    Kodera Y; Takahashi N; Yoshikawa T; Takiguchi N; Fujitani K; Ito Y; Miyamoto K; Takayama O; Imano M; Kobayashi D; Miyashita Y; Morita S; Sakamoto J
    Gastric Cancer; 2017 Jan; 20(1):190-199. PubMed ID: 26879545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of weekly paclitaxel following fixed three cycles of S-1-based chemotherapy for advanced gastric cancer.
    Ohashi M; Kanda T; Kobayashi T; Hirota M; Hayami M; Yajima K; Matsuki A; Kosugi S; Hatakeyama K;
    Hepatogastroenterology; 2011; 58(106):652-8. PubMed ID: 21674889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.